Health Canada grants marketing approval for Takeda ’s multiple myeloma treatment
Health Canada has approved Japanese-based Takeda Pharmaceutical Company ’s Ninlaro (ixazomib) capsules, in combination with lenalidomide and dexamethasone, to treat patients with multiple myeloma (MM). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 9, 2016 Category: Pharmaceuticals Source Type: news
Health Canada grants marketing approval for Takeda ’s multiple myeloma teatment
Health Canada has approved Japanese-based Takeda Pharmaceutical Company ’s Ninlaro (ixazomib) capsules, in combination with lenalidomide and dexamethasone, to treat patients with multiple myeloma (MM). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 9, 2016 Category: Pharmaceuticals Source Type: news
Three-Drug Regimen Beneficial for High-Risk Cytogenetic Myeloma Subgroup
Treatment with carfilzomib, lenalidomide, and dexamethasone improved the poor prognosis associated with high-risk cytogenetic abnormalities of multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - August 4, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news
MorphoSys reports positive safety run-in Phase II L-MIND trial results of MOR208 to treat DLBCL
German biotechnology firm MorphoSys has completed the safety run-in phase of its Phase II L-MIND trial of MOR208 combined with lenalidomide, to treat relapsed or refractory diffuse large B cell lymphoma (DLBCL). (Source: Drug Development Technology)
Source: Drug Development Technology - August 3, 2016 Category: Pharmaceuticals Source Type: news
Sales of flagship drug Revlimid drive Celgene profit; forecast raised
NEW YORK (Reuters) - Celgene Corp raised its 2016 profit forecast and exceeded expectations for second-quarter earnings on Thursday on the strength of its flagship multiple myeloma drug Revlimid and growth in newer medicines, sparking a 2 percent jump in its shares. < div class="feedflare" > < a href="http://feeds.feedburner.com/~ff/reuters/healthNews?a=_O1F1mK6Taw:BUHqFXVWbJA:yIl2AUoC8zA" > < img src="http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA" border="0" > < /img > < /a > < a href="http://feeds.feedburner.com/~ff/reuters/healthNews?a=_O1F1mK6Taw:BUHqFXVWbJA:F7zBnMyn0Lo" > < img src="http://feeds.fee...
Source: Reuters: Health - July 28, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
Revlimid Fails to Extend Survival in Lymphoma Study Revlimid Fails to Extend Survival in Lymphoma Study
Celgene Corp said on Monday that its flagship drug Revlimid (lenalidomide) failed to extend survival as a maintenance therapy for a type of blood cancer after patients had responded to prior treatment. < br / > < i > Reuters Health Information < /i > (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 26, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Celgene drug fails to extend survival in lymphoma study
(Reuters) - Celgene Corp said on Monday that its flagship drug Revlimid failed to extend survival as a maintenance therapy for a type of blood cancer after patients had responded to prior treatment. < div class="feedflare" > < a href="http://feeds.feedburner.com/~ff/reuters/healthNews?a=6gJL44kO8vw:9Zma1I7-XPQ:yIl2AUoC8zA" > < img src="http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA" border="0" > < /img > < /a > < a href="http://feeds.feedburner.com/~ff/reuters/healthNews?a=6gJL44kO8vw:9Zma1I7-XPQ:F7zBnMyn0Lo" > < img src="http://feeds.feedburner.com/~ff/reuters/healthNews?i=6gJL44kO8vw:9Zma1I7-XPQ:F7zBnMy...
Source: Reuters: Health - July 25, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
Early Treatment of Smoldering Myeloma: Is It Time?Early Treatment of Smoldering Myeloma: Is It Time?
The combination lenalidomide and dexamethasone has been shown to delay the progression of smoldering multiple myeloma. So should this approach be used in clinical practice? Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 19, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Early Treatment of Smoldering Myeloma: Is It Time? Early Treatment of Smoldering Myeloma: Is It Time?
The combination lenalidomide and dexamethasone has been shown to delay the progression of smoldering multiple myeloma. So should this approach be used in clinical practice? < br / > < i > Medscape Medical News < /i > (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 19, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
REVLIMID(R) (Lenalidomide) Approved by the European Commission for the Treatment of Relapsed/Refractory Patients with Mantle Cell Lymphoma
BOUDRY, Switzerland--(Healthcare Sales & Marketing Network)--Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (CELG) today announced that the European Commission (EC) has approved REVLIMID® (lenalidomide) for the trea... Biopharmaceuticals, Oncology, RegulatoryCelgene International Sàrl, REVLIMID, lenalidomide, mantle cell lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 15, 2016 Category: Pharmaceuticals Source Type: news
Lenalidomide Helps Some With Myelodysplastic SyndromesLenalidomide Helps Some With Myelodysplastic Syndromes
In certain patients with lower risk myelodysplastic syndromes, lenalidomide (Revlimid, Celgene) can improve quality of life and reduce the need for red blood cell (RBC) transfusions, according to findings from international investigators. Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - July 6, 2016 Category: Pathology Tags: Pathology & Lab Medicine News Source Type: news
Lenalidomide Combination Trumps Older Drugs for Multiple MyelomaLenalidomide Combination Trumps Older Drugs for Multiple Myeloma
Lenalidomide plus dexamethasone more effectively treats newly diagnosed multiple myeloma patients ineligible for stem-cell transplantation, regardless of age, than a triplet of older drugs, researchers report. Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - June 29, 2016 Category: Pathology Tags: Hematology-Oncology News Source Type: news
Revlimid Cuts Transfusion Need in Some MDS Patients (CME/CE)
(MedPage Today) -- But no quality of life benefit seen in trial (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 29, 2016 Category: Hematology Source Type: news
Lenalidomide Maintenance 'Clear Standard' After Transplant Lenalidomide Maintenance 'Clear Standard' After Transplant
Lenalidomide maintenance therapy after stem cell transplant in multiple myeloma increases survival compared with placebo, a new meta-analysis confirms. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 27, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
New Analyses From Pivotal Phase 3 Studies Show Kyprolis ® (Carfilzomib) Allows Patients With Relapsed Multiple Myeloma To Live Longer Without Disease Progression
Cumulative Rates of Complete Response or Better Increased Over Time in Patients Treated With Kyprolis in Combination With Lenalidomide and Dexamethasone (KRd)
In a Post-Hoc Analysis, Treatment With KRd for 18 Months Reduced Risk of Progression or Death by 42 Percent During That Period
Additional Analyses Showed Kyprolis Plus Dexamethasone (Kd) was Superior to Bortezomib Plus Dexamethasone (Vd) Across Patient Populations
THOUSAND OAKS, Calif., June 10, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a post-hoc analysis of the pivotal Phase 3 ASPIRE study which highlighted the benefit of conti...
Source: Amgen News Release - June 10, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
